Hexarelin — the potent GH secretagogue with cardiac effects

That discovery complicated an already complicated compound in ways that the field is still working through.

Hexarelin is the most potent of the older growth hormone-releasing peptide series. It shares structural ancestry with GHRP-6 — both are six-amino-acid synthetic peptides that activate the ghrelin receptor, GHS-R1a — but two substitutions in Hexarelin's amino acid sequence produce substantially stronger GH release than either GHRP-6 or GHRP-2 at equivalent doses. When Italian researchers at the University of Turin began characterizing it in the early 1990s, the GH stimulation was striking enough to generate real pharmaceutical interest. Here was a compound that hit the GHS-R1a receptor harder than its predecessors and produced correspondingly larger GH pulses.

The GH stimulation mechanism is the same as the rest of the GHRP family: Hexarelin activates the ghrelin receptor in the pituitary, the pituitary releases growth hormone, and the normal somatostatin-mediated feedback loop governs the ceiling on that response. The pituitary can't be pushed past physiological limits by GHS-R1a agonism the way it can by direct GH injection, because the brake system stays intact. What Hexarelin produces is a robust, feedback-governed GH pulse — larger than GHRP-6, larger than GHRP-2, larger than Ipamorelin.

And then it does something else.

The cardiac effects of Hexarelin became one of the more unusual threads in secretagogue research. Preclinical studies — mostly in rat and pig models, which means the translation to human physiology requires caution — showed that Hexarelin appeared to protect cardiac tissue from ischemic injury, improve contractility in failing hearts, and reduce myocardial fibrosis. These effects were observed even when growth hormone itself was absent from the picture. Researchers used GH-deficient animal models and found that the cardiac signal persisted, which meant the mechanism wasn't mediated through GH acting downstream. The heart was responding to Hexarelin directly.

The receptor responsible appears to be CD36, a scavenger receptor expressed on cardiac cells and other tissues that is involved in lipid uptake, cell adhesion, and signaling. CD36 is structurally and functionally distinct from GHS-R1a. Hexarelin binds to it. The downstream effects of that binding, in preclinical models, include effects on cardiac cell survival, mitochondrial function, and protection against oxidative stress in heart tissue. This is a different pharmacological action occurring in parallel with the GHS-R1a-mediated GH release — the same molecule knocking on two very different doors at once. The Italian cardiology research community found this interesting enough to sustain a thread of investigation that continued well into the 2000s.

None of this has translated into a clinical application. Hexarelin is not FDA-approved for any cardiac indication. The preclinical cardiac data is genuine and the mechanism is biologically coherent, but the path from promising animal models to a clinical cardiac drug is long, expensive, and uncertain, and that path was never completed. The cardiology research thread is worth understanding because it explains why Hexarelin attracted the kind of scientific attention it did, and because the CD36 receptor story is a reminder that peptides with multiple binding targets produce multiple effects — some intended, some unexpected, some potentially useful, all requiring evaluation.

The serious practical problem with Hexarelin is desensitization. Of the older GHRPs, Hexarelin produces the most rapid and pronounced receptor downregulation. The GHS-R1a receptor adapts to sustained agonist exposure by reducing its surface expression and signaling sensitivity — a standard homeostatic response to persistent activation. Under Hexarelin, this happens faster and more completely than under GHRP-6 or GHRP-2. Researchers and clinicians who worked with the compound in body-composition or recovery contexts found that the robust GH pulse seen on day one was substantially attenuated by week three or four of continuous use, and significantly blunted by week eight. The most potent compound in the series became the least sustainable for sustained protocols.

This is the central paradox of Hexarelin. Its potency — the property that made it most interesting — is exactly what produces the fastest burnout. The receptor doesn't distinguish between a strong signal and an overwhelming one; it responds to persistent activation by becoming less responsive. Cycling became a practical necessity for anyone trying to use Hexarelin for extended periods: use for two to four weeks, break for several weeks to allow receptor resensitization, repeat. The logistics of that cycling requirement, combined with the need for frequent subcutaneous injections and the monitoring required to track desensitization, made Hexarelin a difficult compound to use in sustained protocols compared to Ipamorelin, which desensitizes much more slowly and allows for more consistent long-term use.

The appetite and cortisol effects follow the GHRP family pattern. Hexarelin produces appetite stimulation through GHS-R1a activation, consistent with the ghrelin-mimetic nature of all compounds in this class. The appetite drive is generally considered less pronounced than GHRP-6's but comparable to or somewhat greater than GHRP-2's — though individual response varies and the comparative data isn't exhaustive. Cortisol and prolactin elevations occur alongside the GH pulse, as they do with GHRP-2 and GHRP-6. These elevations are modest and transient at acute doses. In cycling protocols designed to prevent desensitization, the total cortisol exposure over any given month is limited by the nature of the cycling itself, but this is a consideration for any sustained use.

Why does Hexarelin remain in research and compounding circulation given these limitations? Part of it is inertia — the compound has been around long enough that it has an established presence in the compounding pharmacy ecosystem and a body of prescribing experience. Part of it is the potency advantage in specific applications: there are circumstances where a very large GH pulse for a limited period is more useful than a moderate GH pulse sustained over months, and Hexarelin can deliver that. And part of it is the CD36 receptor story — the cardiac research thread created a scientific interest in Hexarelin that is genuinely distinct from its GH-stimulation profile, and that interest keeps it on the research agenda even as its body-composition application has narrowed.

Hexarelin is not FDA-approved. It exists in compounded formulations, accessed through prescribing providers, outside the standard pharmaceutical pathway. The preclinical evidence for its cardiac effects is intriguing; the human data is not sufficient to support clinical claims. The GH stimulation is real and well-documented. The desensitization problem is real and well-documented. A decision to include Hexarelin in any protocol — rather than the more consistently manageable Ipamorelin — requires understanding specifically what property of Hexarelin you're trying to leverage and why the trade-off with desensitization is acceptable for that purpose.

The honest picture of Hexarelin is a compound that made the field understand the upper boundary of what GHS-R1a agonism could accomplish. It was the furthest the older GHRP series went in pursuit of potency. What it found at that boundary — the cardiac signaling, the rapid desensitization, the multi-receptor pharmacology — was information as much as it was a tool. Newer secretagogues were designed partly by looking at Hexarelin and deciding which parts of its profile to keep and which to engineer away. Most of what Hexarelin does so forcefully turns out to be something the field decided to do more gently.